Compare Abeona Therapeutics Inc (ABEO) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hut 8 Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Hut 8 Corp trades at $98.08 (market cap $10.89B). The key difference: Hut 8 Corp is far larger — about 29.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | HUT | |
|---|---|---|
Market Cap | $373.32M | $10.89B |
Sector | Health | Technology |
52-Week High | $7.23 | $133.02 |
52-Week Low | $4.17 | $19.45 |
Enterprise Value | $228.22M | $11.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HUT trades at $103.78, up 6.84% today, but faces bearish technical signals with resistance at $108. The company shows strong analyst support (93.75% buy ratings) with a $129.44 consensus target, yet fundamentals reveal challenges: negative net income margin of -109.77% in 2025 and operating cash flow of -$139.23M. Recent news highlights Hut 8's pivot to AI infrastructure, closing $4.25B in project financing for data centers, signaling strategic growth amid profitability concerns.
Outlook: High growth potential from AI/data center expansion, but elevated execution risks and persistent losses warrant caution. Near-term price movement may hinge on Q2 2026 earnings (expected EPS -$0.32) and Bitcoin market volatility. Risks include competitive pressures and reliance on financing for cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
